Public procurement notice: Contract Notice
Published: 2019-07-25
Buyer: Agència de Qualitat i Avaluació Sanitària de Catalunya
Country: ES
Contract type: Services
Procedure: Open procedure
CPV classification: 33000000 | 38000000 | 48180000 | 72000000 | 73100000
Estimated value: 2848450.41 EUR
Submission deadline: 2019-10-28
Award criteria: The most economic tender
EU fund: Horizon Europe

Technical requirements: Pre–commercial Procurement to buy R&D Services to Early Detecting Micro‐organisms that may Determine the Incurrence of Hospital-Acquired Infections and to Controlling the Diffusion of Infections
The procurement aims to trigger new solutions to be developed and tested to address the following challenges:
— reducing both the healthcare and governmental costs and the operational impact resulting from infections caused by MDROs,
— reducing the community and social care impact of MDROs acquired at hospitals through technologies that will transform current surveillance and Infections control systems into new comprehensive systems.
This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (so-called ‘buyers group’).
For each Phase at least 51 % of the R&D services need to be performed within the EU Member States, or a country that is associated to the Horizon 2020.
This is a joint procurement involving different countries, and the state applicable national procurement law is the Spanish one.
The lead procurer (Agència de Qualitat i Avaluació Sanitària de Catalunya) is appointed to coordinate and lead the joint PCP, and to sign and award the framework agreement and the specific contracts for all phases of the PCP, in the name and on behalf of the following buyers group:
The procurement will take the form of a pre-Commercial Procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.
Each selected operator will be awarded a framework agreement that covers 3 R&D phases. The 3 phases are:
— R&D up to original development, validation and testing of a limited set of first products or services.
Testing is expected to take place in the facilities of the members of the buyers group FMT, PAT and Helios.
This testing may also serve as a first customer test reference for the contractors. The procurement – from the tender procedure until the subsequent performance of contracts – is expected to start in 28.7.2019 and to end in 31.8.2021.
The selected operators will retain ownership of the Intellectual Property Rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions beyond the procurers.
This procurement receives funding from the European Union’s Horizon 2020 Research and Innovation Programme (H2020-EU.2.1. - INDUSTRIAL LEADERSHIP- Leadership in enabling and industrial technologies- Information and Communication Technologies (ICT)) under Grant Agreement No.688878. The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.


Award value: 2848450.41